We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceuticals and AstraZeneca have settled patent litigation with a licensing agreement that enables Teva to market and manufacture a generic version of AstraZeneca’s diabetes drug Byetta.